$MTZ

MASTEC INC

No enriched coverage for $MTZ in the last 7 days.

No SEC Form 4 filings for $MTZ in the last 30 days.

Med

MasTec (MTZ) Surpasses Q1 Earnings and Revenue Estimates

MasTec (MTZ) reported strong first-quarter 2026 results, beating Zacks Consensus Estimates for both earnings and revenue. The company posted earnings of $1.39 per share, exceeding the $0.98 estimate, and revenues of $3.83 billion, surpassing the $3.47 billion estimate. Despite outperforming the market year-to-date, the stock currently holds a Zacks Rank #3 (Hold) based on mixed estimate revisions.

MasTec Inc (MTZ) Shares Surge 6.3% -- What GF Score of 82 Tells Investors

MasTec Inc (MTZ) shares surged 6.3% to $394.05, representing a 209.5% increase over the past year. Despite a strong GF Score of 82/100, indicating solid fundamentals and growth, the stock is considered significantly overvalued at its current price compared to its GF Value estimate of $149.15. Additionally, insider selling of $2.3 million in the last three months raises caution for potential investors.

Chicago Capital LLC Raises Stake in MasTec, Inc. $MTZ

Chicago Capital LLC significantly increased its stake in MasTec, Inc. (NYSE:MTZ) by 190.3% in the fourth quarter, now holding 6,621 shares valued at approximately $1.44 million. This move aligns with a broader bullish sentiment from analysts, who have raised price targets for MTZ, including Stifel to $401 and JPMorgan to $386. MasTec has also reported strong financial performance, beating Q4 revenue and EPS estimates and providing optimistic FY2026 guidance, with shares trading near a 12-month high.